Tclin VEGFA Vascular endothelial growth factor A

Protein Summary

Description

Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity). This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. [provided by RefSeq, Nov 2015]

Uniprot Accession IDs

• P15692
• B5BU86
• H0Y2S8
• H0Y407
• H0Y414
• H0Y462
• H0Y8N2
• H3BLW7
• O60720
• O75875
• Q074Z4
• Q16889
• Q5UB46
• Q6P0P5
• Q96KJ0
• Q96L82
• Q96NW5
• Q9H1W8
• Q9H1W9
• Q9UH58
• Q9UL23
• VEGF-A

Gene Name

• VEGFA

Ensembl ID

• ENST00000372077
• ENSP00000361148
• ENSG00000112715
• ENST00000457104
• ENSP00000409911
• ENST00000518689
• ENSP00000430829
• ENST00000518824
• ENSP00000430002
• ENST00000520948
• ENSP00000428321
• ENST00000523125
• ENSP00000429008
• ENST00000523873
• ENSP00000430479
• ENST00000523950
• ENSP00000429643
• ENST00000611736
• ENSP00000478570
• ENST00000615393
• ENSP00000478034
• ENST00000617771
• ENSP00000484284
• ENST00000621747
• ENSP00000483241
• ENST00000640482
• ENSP00000492800
• ENST00000640499
• ENSP00000492413
• ENST00000640653
• ENSP00000492199

Symbol

• VEGF
• VPF
• VEGF
• MVCD1

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
biological process	1
biological term	1
chemical	1
disease	1
small molecule perturbation	0.97

Protein Classes

PANTHER Classes

Protein / Signaling Molecule / Growth Factor / Vascular Endothelial Growth Factor A

DTO Classes

Protein / Signaling / Growth Factor / Vascular Endothelial Growth Factor A

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 34645.72   (req: < 5)

Gene RIFs: 4810   (req: <= 3)

Antibodies: 2331   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 34645.72   (req: >= 5)

Gene RIFs: 4810   (req: > 3)

Antibodies: 2331   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 121

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligands: 32

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drugs: 6